280 related articles for article (PubMed ID: 19384840)
1. Antiproteinuric effect of olmesartan in patients with IgA nephropathy.
Tomino Y; Kawamura T; Kimura K; Endoh M; Hosoya T; Horikoshi S; Utsunomiya Y; Yasuda T; Toyoda M; Tsuge T; Kaneko K
J Nephrol; 2009; 22(2):224-31. PubMed ID: 19384840
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
Nakamura T; Inoue T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H; Node K
Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
Horita Y; Taura K; Taguchi T; Furusu A; Kohno S
Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
[TBL] [Abstract][Full Text] [Related]
5. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
6. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
7. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension.
Smolensky MH; Hermida RC; Portaluppi F
Chronobiol Int; 2007; 24(1):171-81. PubMed ID: 17364587
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
10. The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies.
Goyache-Goñi B; Aranda-Lara P; Reyes-Engels A; Frutos-Sanz MA; Hernández-Marrero D
Nefrologia; 2013 Nov; 33(6):771-8. PubMed ID: 24241364
[TBL] [Abstract][Full Text] [Related]
11. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.
Szeto CC; Chow KM; Kwan BC; Chung KY; Leung CB; Li PK
Am J Kidney Dis; 2008 May; 51(5):724-31. PubMed ID: 18436082
[TBL] [Abstract][Full Text] [Related]
12. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
13. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function.
Palla R; Panichi V; Finato V; Parrini M; Andreini B; Bianchi AM; Giovannini L; Migliori M; Bertelli AA
Int J Clin Pharmacol Res; 1994; 14(1):35-43. PubMed ID: 7927959
[TBL] [Abstract][Full Text] [Related]
14. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
[TBL] [Abstract][Full Text] [Related]
16. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
[TBL] [Abstract][Full Text] [Related]
17. Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases.
Park HC; Choi HY; Kim BS; An HR; Lee JS; Ha SK; Han DS
Biomed Pharmacother; 2009 Nov; 63(9):672-8. PubMed ID: 19278811
[TBL] [Abstract][Full Text] [Related]
18. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.
Naya M; Tsukamoto T; Morita K; Katoh C; Furumoto T; Fujii S; Tamaki N; Tsutsui H
J Am Coll Cardiol; 2007 Sep; 50(12):1144-9. PubMed ID: 17868805
[TBL] [Abstract][Full Text] [Related]
20. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
